DLBS 3233

Drug Profile

DLBS 3233

Alternative Names: DLBS-3233; Inlacin

Latest Information Update: 11 Jun 2015

Price : $50

At a glance

  • Originator Dexa Medica
  • Class Antihyperglycaemics; Thiazolidinediones
  • Mechanism of Action Adiponectin stimulants; GLUT4 stimulants; Lipoprotein modulators; Peroxisome proliferator-activated receptor gamma modulators; Phosphatidylinositol 3 kinase alpha modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Polycystic ovary syndrome

Most Recent Events

  • 11 Jun 2015 No recent reports of development identified - Phase-III for Type-2 diabetes mellitus (Prevention) in Indonesia (PO)
  • 01 Oct 2014 Dexa Medica initiates enrolment in the phase III PROSTIF trial for Polycystic ovary syndrome in Indonesia (NCT01999686)
  • 01 Sep 2014 Dexa Medica completes a phase III trial in Type-2 diabetes mellitus in Indonesia (NCT01645332)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top